Amlexanox
TBK1 inhibitor / Antidiabetic / Improves obesity-related metabolic dysfunction in mouse models.1 Increases thermogenesis and weight loss, decreases steatosis and improves insulin sensitivity. Inhibits TANK-binding kinase 1 (TBK1) and IKK (IC50=1.2 uM).2 Clinically useful in the treatment of aphthus ulcers.3 Inhibits prostate tumor metastasis by targeting IKK/TBK1/NFB signaling.4
Biochemicals & reagents
68302-57-8
1) Koch et al. (2013), Obesity: Teaching an old drug new tricks - amlexanox targets inflammation to improve metabolic dysfunction; Nat. Rev. Endocrinol., 9 185 2) Reilly et al. (2013), An inhibitor of the protein kinases TBK1 and IKK-? improves obesity-related metabolic dysfunctions in mice; Nat. Med., 19 313 3) Nasry et al. (2016), Different modalities for treatment of recurrent aphthous stromatitis. A Randomized clinical trial; J. Clin. Exp. Dent. 8 e517 4) Cheng et al. (2018), Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKK?/TBK1/NF?B signaling; Theranostics 8 4633
RT
TARGET: Kinase; GPCR -- PATHWAY: NFkappaB; Histamine; Glycation; Cytokine -- RESEARCH AREA: Immunology -- DISEASE AREA: Obesity; Liver diseaseDiabetes; Inflammation; Cancer